Literature DB >> 17283138

RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of beta-catenin by interacting with betaTrCP.

Emilie Estrabaud1, Irina Lassot, Guillaume Blot, Erwann Le Rouzic, Valérie Tanchou, Eric Quemeneur, Laurent Daviet, Florence Margottin-Goguet, Richard Benarous.   

Abstract

The Ras-association domain family 1 (RASSF1) gene has seven different isoforms; isoform A is a tumor-suppressor gene (RASSF1A). The promoter of RASSF1A is inactivated in many cancers, whereas the expression of another major isoform, RASSF1C, is not affected. Here, we show that RASSF1C, but not RASSF1A, interacts with betaTrCP. Binding of RASSF1C to betaTrCP involves serine 18 and serine 19 of the SS(18)GYXS(19) motif present in RASSF1C but not in RASSF1A. This motif is reminiscent of the canonical phosphorylation motif recognized by betaTrCP; however, surprisingly, the association between RASSF1C and betaTrCP does not occur via the betaTrCP substrate binding domain, the WD40 repeats. Overexpression of RASSF1C, but not of RASSF1A, resulted in accumulation and transcriptional activation of the beta-catenin oncogene, due to inhibition of its betaTrCP-mediated degradation. Silencing of RASSF1A by small interfering RNA was sufficient for beta-catenin to accumulate, whereas silencing of both RASSF1A and RASSF1C had no effect. Thus, RASSF1A and RASSF1C have opposite effects on beta-catenin degradation. Our results suggest that RASSF1C expression in the absence of RASSF1A could play a role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283138     DOI: 10.1158/0008-5472.CAN-06-2530

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.

Authors:  Erika da Costa Prando; Luciane Regina Cavalli; Cláudia Aparecida Rainho
Journal:  Epigenetics       Date:  2011-12       Impact factor: 4.528

2.  Targeted polyubiquitylation of RASSF1C by the Mule and SCFβ-TrCP ligases in response to DNA damage.

Authors:  Xin Zhou; Ting-Ting Li; Xu Feng; Esther Hsiang; Yue Xiong; Kun-Liang Guan; Qun-Ying Lei
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

Review 3.  Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

Authors:  P Mapelli; E O Aboagye; J Stebbing; R Sharma
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

Review 4.  Tumor suppressor C-RASSF proteins.

Authors:  Hiroaki Iwasa; Shakhawoat Hossain; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2018-01-20       Impact factor: 9.261

5.  The RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells.

Authors:  Angelique W Whitehurst; Rosalyn Ram; Latha Shivakumar; Boning Gao; John D Minna; Michael A White
Journal:  Mol Cell Biol       Date:  2008-03-17       Impact factor: 4.272

6.  Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis.

Authors:  Mark E Reeves; Scott W Baldwin; Melissa L Baldwin; Shin-Tai Chen; Jeremy M Moretz; Robert J Aragon; Xinmin Li; Donna D Strong; Subburaman Mohan; Yousef G Amaar
Journal:  BMC Cancer       Date:  2010-10-18       Impact factor: 4.430

7.  Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A.

Authors:  M Lee Schmidt; Howard Donninger; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

8.  Multiple isoforms of beta-TrCP display differential activities in the regulation of Wnt signaling.

Authors:  Eunjeong Seo; Hyunjoon Kim; Rokki Kim; Sangmoon Yun; Minseong Kim; Jin-Kwan Han; Frank Costantini; Eek-Hoon Jho
Journal:  Cell Signal       Date:  2008-09-25       Impact factor: 4.315

9.  RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression.

Authors:  Rosalyn R Ram; Saurabh Mendiratta; Brian O Bodemann; Michael J Torres; Ugur Eskiocak; Michael A White
Journal:  Mol Cell Biol       Date:  2014-04-14       Impact factor: 4.272

10.  HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.

Authors:  Bastien Mangeat; Gustavo Gers-Huber; Martin Lehmann; Madeleine Zufferey; Jeremy Luban; Vincent Piguet
Journal:  PLoS Pathog       Date:  2009-09-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.